NR 546 Week 3 Antipsychotics Table Advanced Pharmacology (Verified) - Chamberlain College.
Drug name Indication Half-life Notable side effects (associate to pathway or NT)
Target symptoms: state if positive or negative effect (T1/2),
Potency (if noted. receptor occupancy if noted ) metabolism
Neurotransmitter(s) affected (CYP 450
enzyme)
Typical antipsychotics (conventional)
Haloperidol Manifestations of psychotic disorders Tics and vocal Half-Life: • Neuroleptic-induced deficit syndrome
utterances in Tourette’s Syndrome Second-line Haldol • Akathisia
treatment of severe behavior problems in children decanoate: • Drug-induced parkinsonism
of combative, explosive, hyperexcitability approximat • Tardive dyskinesia, dystonia
Secondline short-term treatment of hyperactive ely 3 weeks • Irreversible involuntary dyskinetic
children Treatment of schizophrenic patients who Oral: 12-38 movements Galactorrhea, amenorrhea
require prolonged parenteral antipsychotic therapy hours Dizziness, sedation Dry mouth
Bipolar Disorder Behavioral disturbances in Metabolism: • Constipation
dementias Delirium (with lorazepam) Positive CYP1A2, • Urinary retention
symptoms of psychosis, violent or aggressive CYP2D6, • Blurred vision
behavior Potency: High potency first-generation CYP3A4 • Decreased sweating
Neurotransmitter(s) affected:
Blocks dopamine 2 receptors, reducing positive • Hypotension
symptoms of psychosis and combative, explosive, and • Tachycardia
hyperactive behaviors Blocks dopamine 2 receptors in • Hypertension
the nigrostriatal pathway, improving tics and other • Weight gain
symptoms in Tourette’s syndrome
,NR 546 Week 3 Antipsychotics Table Advanced Pharmacology (Verified) - Chamberlain College.
Thioridazine Target symptoms: Used for Schizophrenia in patients Half-Life: • Neuroleptic-induced deficit syndrome
who fail to respond to treatment with other 21-24 hours • Akathisia
antipsychotic drugs Positive symptoms of psychosis Metabolism: • Priapism
Motor and autonomic hyperactivity Violent or CYP450 2D6 • Drug-induced parkinsonism
aggressive behavior • Tardive dyskinesia
Potency: Low-potency first-generation • Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 • Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis • Pigmentary retinopathy
• Dizziness, sedation
Thiothixene Target symptoms: Schizophrenia, other psychotic Half-Life: Neuroleptic-induced deficit syndrome
disorders, bipolar disorder Reduces positive 34-35 hours • Akathisia
symptoms in schizophrenia Reduces symptoms of Metabolism: • Drug-induced parkinsonism
acute psychotic mania Reduces negative symptoms of CYP1A2 • Tardive dyskinesia
psychosis Potency: High potency conventional • Irreversible involuntary dyskinetic movements
antipsychotic Neurotransmitter(s) affected: Blocks • Galactorrhea, amenorrhea
dopamine 2 receptors, reducing positive symptoms of • Sedation
psychosis • Dry Mouth
• Constipation
• Vision disturbance
• Urinary retention
• Hypotension
• Tachycardia
• Rare fine lenticular pigmentation
, NR 546 Week 3 Antipsychotics Table Advanced Pharmacology (Verified) - Chamberlain College.
Fluphenazine arget symptoms: Psychotic disorders, bipolar disorder Half-Life:
Positive symptoms of psychosis Motor and autonomic 14-16 hours Fluphenazine Target symptoms: Psychotic
hyperactivity Violent or aggressive behavior Metabolism: disorders, bipolar disorder Positive symptoms of
Potency: High potency conventional antipsychotic CYP2D6 psychosis Motor and autonomic hyperactivity
Neurotransmitter(s) affected: Blocks dopamine 2 Violent or aggressive behavior
receptors, reducing positive symptoms of psychosis Potency: High potency conventional antipsychotic
Neurotransmitter(s) affected: Blocks dopamine 2
receptors, reducing positive symptoms of psychosis
Half-Life: 14-16
hours
Metabolism: CYP2D6
• Neuroleptic-induced deficit syndrome
• Akathisia
• Drug-induced parkinsonism
• Tardive dyskinesia
• Irreversible involuntary dyskinetic movements
• Galactorrhea, amenorrhea
• Dizziness, sedation
• Dry mouth
• Constipation
• Urinary retention
• Blurred vision
• Decreased sweating
• Depression
• Sexual dysfunction
• Hypotension
• Tachycardia
• Syncope
• Weight gain
Drug name Indication Half-life Notable side effects (associate to pathway or NT)
Target symptoms: state if positive or negative effect (T1/2),
Potency (if noted. receptor occupancy if noted ) metabolism
Neurotransmitter(s) affected (CYP 450
enzyme)
Typical antipsychotics (conventional)
Haloperidol Manifestations of psychotic disorders Tics and vocal Half-Life: • Neuroleptic-induced deficit syndrome
utterances in Tourette’s Syndrome Second-line Haldol • Akathisia
treatment of severe behavior problems in children decanoate: • Drug-induced parkinsonism
of combative, explosive, hyperexcitability approximat • Tardive dyskinesia, dystonia
Secondline short-term treatment of hyperactive ely 3 weeks • Irreversible involuntary dyskinetic
children Treatment of schizophrenic patients who Oral: 12-38 movements Galactorrhea, amenorrhea
require prolonged parenteral antipsychotic therapy hours Dizziness, sedation Dry mouth
Bipolar Disorder Behavioral disturbances in Metabolism: • Constipation
dementias Delirium (with lorazepam) Positive CYP1A2, • Urinary retention
symptoms of psychosis, violent or aggressive CYP2D6, • Blurred vision
behavior Potency: High potency first-generation CYP3A4 • Decreased sweating
Neurotransmitter(s) affected:
Blocks dopamine 2 receptors, reducing positive • Hypotension
symptoms of psychosis and combative, explosive, and • Tachycardia
hyperactive behaviors Blocks dopamine 2 receptors in • Hypertension
the nigrostriatal pathway, improving tics and other • Weight gain
symptoms in Tourette’s syndrome
,NR 546 Week 3 Antipsychotics Table Advanced Pharmacology (Verified) - Chamberlain College.
Thioridazine Target symptoms: Used for Schizophrenia in patients Half-Life: • Neuroleptic-induced deficit syndrome
who fail to respond to treatment with other 21-24 hours • Akathisia
antipsychotic drugs Positive symptoms of psychosis Metabolism: • Priapism
Motor and autonomic hyperactivity Violent or CYP450 2D6 • Drug-induced parkinsonism
aggressive behavior • Tardive dyskinesia
Potency: Low-potency first-generation • Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 • Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis • Pigmentary retinopathy
• Dizziness, sedation
Thiothixene Target symptoms: Schizophrenia, other psychotic Half-Life: Neuroleptic-induced deficit syndrome
disorders, bipolar disorder Reduces positive 34-35 hours • Akathisia
symptoms in schizophrenia Reduces symptoms of Metabolism: • Drug-induced parkinsonism
acute psychotic mania Reduces negative symptoms of CYP1A2 • Tardive dyskinesia
psychosis Potency: High potency conventional • Irreversible involuntary dyskinetic movements
antipsychotic Neurotransmitter(s) affected: Blocks • Galactorrhea, amenorrhea
dopamine 2 receptors, reducing positive symptoms of • Sedation
psychosis • Dry Mouth
• Constipation
• Vision disturbance
• Urinary retention
• Hypotension
• Tachycardia
• Rare fine lenticular pigmentation
, NR 546 Week 3 Antipsychotics Table Advanced Pharmacology (Verified) - Chamberlain College.
Fluphenazine arget symptoms: Psychotic disorders, bipolar disorder Half-Life:
Positive symptoms of psychosis Motor and autonomic 14-16 hours Fluphenazine Target symptoms: Psychotic
hyperactivity Violent or aggressive behavior Metabolism: disorders, bipolar disorder Positive symptoms of
Potency: High potency conventional antipsychotic CYP2D6 psychosis Motor and autonomic hyperactivity
Neurotransmitter(s) affected: Blocks dopamine 2 Violent or aggressive behavior
receptors, reducing positive symptoms of psychosis Potency: High potency conventional antipsychotic
Neurotransmitter(s) affected: Blocks dopamine 2
receptors, reducing positive symptoms of psychosis
Half-Life: 14-16
hours
Metabolism: CYP2D6
• Neuroleptic-induced deficit syndrome
• Akathisia
• Drug-induced parkinsonism
• Tardive dyskinesia
• Irreversible involuntary dyskinetic movements
• Galactorrhea, amenorrhea
• Dizziness, sedation
• Dry mouth
• Constipation
• Urinary retention
• Blurred vision
• Decreased sweating
• Depression
• Sexual dysfunction
• Hypotension
• Tachycardia
• Syncope
• Weight gain
